Hdac4 and hdac5 in the regulation of cardiac gene expression
CA 2382045 A1 · Owner: Olson, Eric N. · Inventors: Mckinsey, Timothy A.; Lu, Jianrong; Olson, Eric N.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to cardiac hypertrophy. More particularly the , present invention defines the molecular events linking calcium stimulation to cardiac hypertrophy. More specifically the present invention shows that Ca2+ stimulation of the hypertrophic response is mediated through an HDAC 4 and 5 interaction with MEF2, and that phosphorylation of HDACs results in loss of HDAC-mediated repression of MEF2 hypertrophic action. Thus the present , invention provides methods and compositions of treating cardiac hypertrophy as well as methods and compositions for identifying subjects at risk for cardiac hypertrophy. Further provided are methods for the detection of compounds …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 21, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended August 21, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 21, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.